Shanghai Yizhong Pharmaceutical688091.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Shanghai Yizhong Pharmaceutical (688091.SH) trades at a P/E of 105.00x, P/B of 4.87x, P/S of 21.90x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 46th percentile over the trailing 10Y window (vs. 34th percentile over 3Y); P/B sits at the 21st percentile over the trailing 10Y window (vs. 19th percentile over 3Y); P/S sits at the 10th percentile over the trailing 10Y window (vs. 16th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 83rd percentile within its industry and the 81st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.48%, ranking at the 76th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 24.9 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Shanghai Yizhong Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 688091 · SSE: 688091 · 688091
Want the full picture on whether Shanghai Yizhong Pharmaceutical (688091.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 105.00 | ||||||
| P/B (MRQ) | 4.87 | ||||||
| P/S (TTM) | 21.90 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.48% |